Nektar gets two presentations at dermatology meeting for drug trials

March 20, 2026 10:00 AM

Nektar Therapeutics (NASDAQ: NKTR) said data from its ongoing Phase 2b studies of rezpegaldesleukin in atopic dermatitis and alopecia areata ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found